Adam Sperling, MD, PhD

What an awesome meeting. Was great to catch up with everyone.

It's my first #newPI roll call on BlueSky! Calling all new #cancer PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! 😃

The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social

Congrats!

Super interesting. Congrats on getting this out.

And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social

Was this article written by GSK?

We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology! ascopubs.org/doi/10.1200/...

Wow. That's insane. How did you respond?

I think it's more insidious that just not understanding drug discovery. This mindset among SV types is part of what justifies their recent destruction of the NIH. If AI will cure disease in 10 years, who needs the universities and research institutes?

As someone directly affected by this, let me be clear:

I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.

Embarrassing...

Looks cold

Yuxin Liu, MD

Meet Yuxin Liu, MD, who treats patients with multiple myeloma and other plasma cell disorders. Her clinical research focuses on novel therapies in newly diagnosed and relapsed multiple myeloma. https://bit.ly/3FljInk

Diet plays a pivotal role in cancer care, yet clear guidelines remain scarce. Dr. Urvi A. Shah explores the evidence, challenges, and need for more robust dietary intervention trials in oncology. ascopost.com/news/march-2...

#OncologyResearch #CancerCare

Multiple myeloma is a terrible disease.

Great news today that my friend and colleague, Dr. Elisabeth Battinelli, has been named chief of classical hematology for Mass General Brigham! Congratulations Beth!
battinellilab.bwh.harvard.edu

Kudos to our professional societies for advocating for continued funding for lifesaving research through the NIH. There is a link at the end of the statement to contact your representatives!! 👇

Flyer for FASEB hematologic malignancies meeting. July 27-31 2025. Southbridge Massachusetts. Keynote speakers: Jennifer Trowbridge and George Vassilou

I feel like we could all use something fun to look forward to right about now!!! 🧪🧪🧪

Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!

events.faseb.org/event/hemato...

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel CRBN-binding agents in myeloma Key Points. CRBN missense mutations identified in patients were modelled to explore their effect on CRBN function with IMiD and CELMoD therapy.Mutations le

ashpublications.org/blood/articl...

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...

Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...

Dana-Farber doctors at the White House.

Three leaders from our cellular therapy & stem cell transplant program were at the White House this week to discuss cell and gene therapy development. We’re grateful to Drs. Corey Cutler, Eric Smith, and Jose Cancelas for their ongoing work to improve access & outcomes with these therapies.

Our latest work is now available to read on bioRxiv! Very proud of this and its potential implications for patients with acute myeloid leukemia 🩸 🧪 🔬💊 **eIF4A-mediated translation initiation as an AML cell vulnerability that can be co-targeted with BCL-2 inhibition** www.biorxiv.org/content/10.1...

Please join us in welcoming Madhav Dhodapkar, MBBS, as the new leader of Fred Hutch’s #Myeloma Program. Dr. Dhodapkar, a board-certified hematologist and oncologist, is a renowned expert in the treatment of multiple myeloma and other hematologic malignancies. #ASH24 1/3

Agreed. We need a robust definition of cure and then we need to design our trials with that in mind.

Interesting. Raises the question of how important the disrupted immune microenvironment is for supporting myeloma growth as opposed to being a consequence of the myeloma and therapy.

The highly anticipated late-breaking abstracts have been posted: bit.ly/2024_ash_lbas

#ASHKudos to the presenters!

Discover high-impact #hematology research at #ASH24! It’s not too late to register to join us in San Diego or virtually.

#BloodSky #HemeSky

I think it’s fundamentally a mistake to think you can have a rational conversation and find decent middle ground with someone like RFK Jr, and that’s what this feels like to me.

An interesting paper in Blood by Dr. Samur suggesting that the cell that eventually becomes myeloma first acquires extra chromosome in 2nd decade of life and becomes fully hyperdiploid by 3rd. Implication for many cancers. @pedalheadphx.bsky.social @auclairdan.bsky.social @szusmani.bsky.social